Founded in September 2019 by academician Ma Dawei and Dr. Tang Guozhi, Shanghai Weishen Pharmaceutical conducts original small‑molecule drug discovery targeting immune regulation, tumor resistance mutations, and functional cure of chronic hepatitis B. The company says it has built an integrated discovery and development platform covering informatics, biology, medicinal chemistry, CMC, preclinical and IND enabling activities, and uses CADD/SBDD and molecular building‑block approaches. Weishen currently has two products approaching IND filing and a pipeline of additional global innovation programs. The company occupies a 1,600 sqm advanced R&D lab and office in Zhangjiang Science City’s Pupu International Medical Park. Earlier angel investors included Hankang Capital and Xingze Capital. Planned uses of the new financing include advancing two projects to IND and into clinical development, deepening differentiated small‑molecule R&D, expanding new technology areas, and growing preclinical and clinical development teams.

Total raised

$16M

Funding rounds

1

Latest round

Series A

Latest activity

Dec 2021